Key result
New oral anticoagulants, including direct anti-Xa and anti-IIa agents, exhibit heterogeneous pharmacological profiles despite their shared indication for stroke prevention in atrial fibrillation.
This review provides a summary of the pharmacological characteristics and mechanisms of action of new direct anti-Xa and anti-IIa oral anticoagulants.
Supports consideration of NOAC heterogeneity in AF; leaves open optimal agent-specific outcome trials.
The new oral anticoagulants are announced as an important therapeutic revolution, particularly after their approval by authorities for stroke prevention in atrial fibrillation. However, the pharmacology of these new drugs is not homogeneous. In this review, we summarize the main pharmacological characteristics of the new direct anti-Xa and anti-IIa agents.
No takes yet. Share an insight, caveat, or question.
Salem et al. (2014) studied this question. New oral anticoagulants, including direct anti-Xa and anti-IIa agents, exhibit heterogeneous pharmacological profiles despite their shared indication for stroke prevention in atrial fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: